170	213	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(0, 0), 'end':(0, 0), 'text':'Discussion'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(1, 0), 'end':(1, 25), 'text':'Understanding the regulation of different isoforms of the class IA PI3Ks is an important goal due to their prominent and isotype specific roles in human diseases'}, {'start':(1, 26), 'end':(1, 40), 'text':'including cancer , diabetes , inflammation , thrombosis , allergy , and cardiac disease .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'condition', 'direction':'RightToLeft', 'children':[{'start':(2, 0), 'end':(2, 9), 'text':'In the absence of activators such as phosphorylated RTKs ,'}, {'start':(2, 10), 'end':(2, 24), 'text':'the basal activity of p110delta is very low , kept tightly suppressed by p85 .'}]}, {'start':(3, 0), 'end':(3, 19), 'text':'Understanding the dynamic interactions between the catalytic and regulatory subunits is important in defining the mechanism of PI3K regulation .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'None', 'children':[{'start':(4, 0), 'end':(4, 20), 'text':'The crystal structure of p110alpha with the niSH2 construct of p85alpha shows contacts formed between the two subunits ( ) ,'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(4, 21), 'end':(4, 25), 'text':'but it does not explain'}, {'start':(4, 26), 'end':(4, 35), 'text':'how these contacts translate into inhibition of the enzyme .'}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(5, 0), 'end':(5, 9), 'text':'DXMS for p110delta and p85alpha has allowed us to interrogate'}, {'start':(5, 10), 'end':(5, 24), 'text':'how contacts between the regulatory and catalytic subunits cause dynamic changes throughout the enzyme .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 0), 'end':(6, 15), 'text':'The presence of the iSH2 caused decreases in exchange all along the crevice of the p110delta'}, {'start':(6, 16), 'end':(6, 37), 'text':'where the iSH2 is predicted to bind ( based on the crystal structures of p110alpha and p110beta complexes ) ( ) .'}]}, {'start':(7, 0), 'end':(7, 25), 'text':'One of the regions in the C2 domain with decreased exchange in the presence of the iSH2 contains Asn334 , equivalent to Asn345 in p110alpha .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 0), 'end':(8, 6), 'text':'This is consistent with the published data'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(8, 7), 'end':(8, 7), 'text':'showing'}, {'start':(8, 8), 'end':(8, 29), 'text':'that the interaction between this residue and Asp560 and Asn564 in the iSH2 participates in the inhibition of p110alpha ( ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 0), 'end':(9, 17), 'text':'The presence of the nicSH2 construct caused decreases in exchange at a region in the helical domain ,'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(9, 18), 'end':(9, 18), 'text':'showing'}, {'start':(9, 19), 'end':(9, 35), 'text':'that the interaction with the nSH2 previously demonstrated for p110alpha is conserved in p110delta ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(10, 0), 'end':(10, 7), 'text':'Decreases were also seen at the C-terminal elbow'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(10, 8), 'end':(10, 11), 'text':'following helix kalpha11 ,'}, {'start':(10, 12), 'end':(10, 21), 'text':'which we predict forms an interface with the cSH2 .'}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(11, 0), 'end':(11, 1), 'text':'We showed'}, {'label':'explanation', 'direction':'LeftToRight', 'children':[{'start':(11, 2), 'end':(11, 13), 'text':'that the p110delta C-terminal region has a critical role in catalysis ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 14), 'end':(11, 17), 'text':'because a deletion construct'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 18), 'end':(11, 35), 'text':'missing the last 17 residues ( from 1028 to 1044 ) had undetectable lipid kinase activity toward PIP2'}, {'start':(11, 36), 'end':(11, 38), 'text':'containing liposomes .'}]}]}]}]}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(12, 0), 'end':(12, 23), 'text':'The C-terminal end of the substrate binding ( activation ) loop also showed decreases in exchange in the presence of various p85alpha constructs ,'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(12, 24), 'end':(12, 35), 'text':'and it is interesting that the more protected this region was ,'}, {'start':(12, 36), 'end':(12, 42), 'text':'the lower the lipid kinase activity .'}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(13, 0), 'end':(13, 13), 'text':'This region would not be predicted to be in contact with the cSH2 ,'}, {'label':'joint', 'direction':'None', 'children':[{'start':(13, 14), 'end':(13, 20), 'text':'and is located directly underneath helix kalpha11'}, {'start':(13, 21), 'end':(13, 32), 'text':'and may represent an allosteric change on rigidification of helix kalpha11 .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(14, 0), 'end':(14, 4), 'text':'The same regions in p110delta'}, {'start':(14, 5), 'end':(14, 24), 'text':'that had decreases in exchange with the nSH2 and cSH2 showed an increase in the presence of PDGFR pY ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(14, 25), 'end':(14, 30), 'text':'restoring the same level of exchange'}, {'start':(14, 31), 'end':(14, 36), 'text':'observed with only the iSH2 .'}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(15, 0), 'end':(15, 2), 'text':'These observations indicate'}, {'start':(15, 3), 'end':(15, 10), 'text':'that breaking these contacts disinhibits the enzyme .'}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(16, 0), 'end':(16, 1), 'text':'We find'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(16, 2), 'end':(16, 15), 'text':'that p110delta and p85alpha disinhibition correlates with increased enzyme affinity for membrane vesicles :'}, {'label':'joint', 'direction':'None', 'children':[{'start':(16, 16), 'end':(16, 24), 'text':'the p110delta and p85alpha complex binds membranes very poorly'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(16, 25), 'end':(16, 41), 'text':'and the addition of PDGFR pY greatly increases the affinity of the p110delta and p85alpha for PIP2'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(16, 42), 'end':(16, 51), 'text':'containing membranes and to a lesser extent also to membranes'}, {'start':(16, 52), 'end':(16, 54), 'text':'lacking PIP2 .'}]}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(17, 0), 'end':(17, 23), 'text':'The binding of the PDGFR pY activated p110delta and p85alpha to membranes is similar to the binding of the free catalytic subunit , DeltaABD-p110delta'}, {'start':(17, 24), 'end':(17, 32), 'text':'that is devoid completely of p85 inhibitory contacts .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(18, 0), 'end':(18, 2), 'text':'This surprising result'}, {'start':(18, 3), 'end':(18, 34), 'text':'that the free catalytic subunit can bind lipid as effectively as the activated p110delta and p85alpha complex contrasts with the hypothesized role of the iSH2 domain in lipid binding ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'start':(19, 0), 'end':(19, 0), 'text':'Regions'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(19, 1), 'end':(19, 20), 'text':'exposed in the kinase domain on PDGFR pY binding had decreases in exchange in the presence of lipid substrate ,'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(19, 21), 'end':(19, 21), 'text':'revealing'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(19, 22), 'end':(19, 33), 'text':'that PDGFR pY binding is critical in exposing regions of the protein'}, {'start':(19, 34), 'end':(19, 40), 'text':'that interact with the lipid membrane .'}]}]}]}]}, {'label':'contrast', 'direction':'RightToLeft', 'children':[{'start':(20, 0), 'end':(20, 23), 'text':'We expected to see changes in the C2 domain due to lipid interaction ( ) , however , we see no significant changes ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(20, 24), 'end':(20, 27), 'text':'but no peptic peptides'}, {'label':'joint', 'direction':'None', 'children':[{'start':(20, 28), 'end':(20, 37), 'text':'covering the CBR3 region of the C2 domain were identified'}, {'start':(20, 38), 'end':(20, 40), 'text':'and analyzed .'}]}]}]}]}, {'label':'background', 'direction':'RightToLeft', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(21, 0), 'end':(21, 6), 'text':'In order to generate a regulatory subunit'}, {'start':(21, 7), 'end':(21, 19), 'text':'that would selectively disrupt the contact between the cSH2 and catalytic domains ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(21, 20), 'end':(21, 25), 'text':'we made a Y685A p85alpha mutant'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(21, 26), 'end':(21, 29), 'text':'based on our finding'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(21, 30), 'end':(21, 32), 'text':'that the peptide'}, {'start':(21, 33), 'end':(21, 42), 'text':'containing this residue becomes exposed on PDGFR pY binding .'}]}]}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(22, 0), 'end':(22, 15), 'text':'This mutation caused an increase in basal activity of p110delta , increased downstream signaling in cells'}, {'label':'temporal', 'direction':'None', 'children':[{'start':(22, 16), 'end':(22, 31), 'text':'and led to exposure of the C-terminal end of the C-lobe and substrate binding loop ,'}, {'start':(22, 32), 'end':(22, 46), 'text':'while not affecting exchange at the helical domain nor the PDGFR pY binding site .'}]}]}]}]}]}]}, {'label':'contrast', 'direction':'None', 'children':[{'start':(23, 0), 'end':(23, 8), 'text':'This engineered mutation in p85alpha also activated recombinant p110beta'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(23, 9), 'end':(23, 14), 'text':'but did not activate p110alpha ,'}, {'start':(23, 15), 'end':(23, 21), 'text':'revealing isoform specific aspects of regulation .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(24, 0), 'end':(24, 16), 'text':'This mutation has been recently found to activate p110beta in a complex with p85beta as well ,'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(24, 17), 'end':(24, 29), 'text':'and the crystal structure of p110beta with the icSH2 construct of p85beta shows'}, {'start':(24, 30), 'end':(24, 50), 'text':'that this Tyr residue is located at the center of the interface between the catalytic and regulatory subunit ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(25, 0), 'end':(25, 5), 'text':'The presence of a previously identified'}, {'start':(25, 6), 'end':(25, 9), 'text':'engineered oncogenic nSH2 mutation'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(25, 10), 'end':(25, 44), 'text':'( K379E ) alone increased the lipid kinase activity and the presence of the double mutant ( K379E , Y685A ) in p85alpha fully activated the enzyme as well as exposing similar regions to exchange'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(25, 45), 'end':(25, 51), 'text':'as in the PDGFR pY activated complex'}, {'start':(25, 52), 'end':(25, 55), 'text':'( D ) .'}]}]}]}, {'start':(26, 0), 'end':(26, 23), 'text':'These p85 point mutations allowed us to isolate specific effects of the nSH2 and cSH2 domains on the dynamics of the p110delta subunit .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'RightToLeft', 'children':[{'start':(27, 0), 'end':(27, 30), 'text':'Based on our results , and using the previously solved structures of p110alpha with the niSH2 construct of p85alpha ( ) and p110beta with the icSH2 construct of p85beta ( )'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(27, 31), 'end':(27, 46), 'text':'we have constructed a model for the regulation of p110delta by the nicSH2 domains of p85alpha'}, {'start':(27, 47), 'end':(27, 50), 'text':'( D ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(28, 0), 'end':(28, 1), 'text':'We propose'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(28, 2), 'end':(28, 23), 'text':'that both the nSH2 and cSH2 play important roles in inhibiting the kinase activity of p110delta , in contrast to p110alpha ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(28, 24), 'end':(28, 30), 'text':'which is inhibited only by the nSH2'}, {'start':(28, 31), 'end':(28, 34), 'text':'( C ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(29, 0), 'end':(29, 13), 'text':'The nSH2 and cSH2 domains prevent binding of p110delta and p85alpha to membranes .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(30, 0), 'end':(30, 6), 'text':'Binding of PDGFR pY breaks inhibitory contacts'}, {'label':'joint', 'direction':'None', 'children':[{'start':(30, 7), 'end':(30, 13), 'text':'formed by the nSH2 andcSH2 with p110delta'}, {'start':(30, 14), 'end':(30, 20), 'text':'and increases affinity for membrane vesicles .'}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(31, 0), 'end':(31, 13), 'text':'Several oncogenic mutations in p85alpha have been recently identified and analyzed ( ) .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(32, 0), 'end':(32, 8), 'text':'Two of them map to regions in the p85'}, {'start':(32, 9), 'end':(32, 32), 'text':'where we see increases in exchange in the presence of PDGFR pY ( L449S in the iSH2 and A682V in the cSH2 ) .'}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(33, 0), 'end':(33, 2), 'text':'We have shown'}, {'start':(33, 3), 'end':(33, 12), 'text':'that the L449S mutation activates the basal enzyme activity .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(34, 0), 'end':(34, 6), 'text':'The presence of the A682V mutation ,'}, {'start':(34, 7), 'end':(34, 21), 'text':'which is located in the proposed interface of the catalytic subunit with the cSH2 ,'}]}, {'start':(34, 22), 'end':(34, 30), 'text':'may contribute to relieving the inhibitory cSH2 contact .'}]}, {'label':'explanation', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(35, 0), 'end':(35, 12), 'text':'Many of the iSH2 mutations are located in or closely adjacent to regions'}, {'start':(35, 13), 'end':(35, 38), 'text':'where we see an increase in exchange in the presence of lipid vesicles ( D464H , D560Y , N564K and D , and L570P ) .'}]}, {'label':'condition', 'direction':'RightToLeft', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(36, 0), 'end':(36, 2), 'text':'Because we show'}, {'start':(36, 3), 'end':(36, 16), 'text':'that interaction with lipid vesicles causes a loosening between the iSH2 and p110delta ,'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(36, 17), 'end':(36, 24), 'text':'these mutations may mimic this membrane mediated loosening'}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(36, 25), 'end':(36, 26), 'text':'and activate'}, {'start':(36, 27), 'end':(36, 35), 'text':'by disrupting the interaction between iSH2 and p110 ,'}]}, {'start':(36, 36), 'end':(36, 41), 'text':'as previously proposed ( ) .'}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(37, 0), 'end':(37, 4), 'text':'This is the first study'}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(37, 5), 'end':(37, 11), 'text':'to examine the dynamic interactions ofheterodimeric complexes'}, {'start':(37, 12), 'end':(37, 23), 'text':'containing the full-length class IA catalytic subunit with its regulatory subunit ,'}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(37, 24), 'end':(37, 25), 'text':'and show'}, {'start':(37, 26), 'end':(37, 40), 'text':'how the addition of PDGFR pY as well as lipid vesicles affects these interactions .'}]}]}]}, {'label':'background', 'direction':'RightToLeft', 'children':[{'start':(38, 0), 'end':(38, 3), 'text':'Based on these ,'}, {'start':(38, 4), 'end':(38, 20), 'text':'we have identified a novel isoform specific regulatory function for the cSH2 of p85alpha with p110delta .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(39, 0), 'end':(39, 7), 'text':'For the first time , we have shown'}, {'start':(39, 8), 'end':(39, 22), 'text':'that RTK pY peptide binding directly increases membrane binding of the class IA heterodimer .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(40, 0), 'end':(40, 7), 'text':'We mapped multiple regions of an activated PI3K'}, {'label':'joint', 'direction':'None', 'children':[{'start':(40, 8), 'end':(40, 11), 'text':'that interact with membranes'}, {'start':(40, 12), 'end':(40, 22), 'text':'and provide experimental evidence for the dynamic interaction with lipids .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(41, 0), 'end':(41, 12), 'text':'The gain in exposure in some regions in the presence of membranes indicates'}, {'start':(41, 13), 'end':(41, 27), 'text':'that loosening of interactions between the p110delta and p85alpha complex accompanies catalysis on membranes .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(42, 0), 'end':(42, 5), 'text':'Our DXMS results provide a framework'}, {'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(42, 6), 'end':(42, 12), 'text':'for designing further structural and biochemical approaches'}, {'start':(42, 13), 'end':(42, 24), 'text':'to understand regulation of the PI3K and PI3K like enzyme families .'}]}]}]}]}]}]}
0	1	{'start':(0, 0), 'end':(0, 17), 'text':'Dynamics of the Phosphoinositide 3-Kinase p110delta Interaction with p85alpha and Membranes Reveals Aspects of Regulation Distinct from p110alpha'}
245	248	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'textual-organization', 'direction':'None', 'children':[{'start':(0, 0), 'end':(0, 1), 'text':'Supplemental Information'}, {'start':(1, 0), 'end':(1, 2), 'text':'Document S1 .'}]}, {'start':(2, 0), 'end':(2, 9), 'text':'Seven Figures , One Table , and Supplemental Experimental Procedures'}]}
213	245	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(0, 0), 'end':(0, 1), 'text':'Experimental Procedures'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(1, 0), 'end':(1, 4), 'text':'Protein Expression and Kinase Assays'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 0), 'end':(2, 7), 'text':'All protein constructs were expressed in Sf9 cells'}, {'start':(2, 8), 'end':(2, 15), 'text':'as described for the DeltaABD-p110delta ( ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 0), 'end':(3, 6), 'text':'Full details are described in the .'}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 0), 'end':(4, 2), 'text':'Lipid Kinase Assays'}, {'start':(5, 0), 'end':(5, 21), 'text':'The lipid kinase activity was determined using a modified membrane capture assay measuring production of 32 P labeled PIP3 ( ) .'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(6, 0), 'end':(6, 11), 'text':'Lipid vesicles were used at a final concentration of 1mg and ml'}, {'start':(6, 12), 'end':(6, 49), 'text':'and were composed of 5 % brain PIP2 , 20 % brain PS , 45 % brain PE , 15 % brain PC , 10 % cholesterol , and 5 % sphingomyelin ( Avanti Polar Lipids ) .'}]}]}]}, {'start':(7, 0), 'end':(7, 5), 'text':'Vesicle preparation is described in .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 0), 'end':(8, 13), 'text':'The lipid solution was mixed with each protein construct , with a final buffer'}, {'start':(8, 14), 'end':(8, 33), 'text':'containing 3mM MgCl 2 , 1mM EGTA , 20mM Tris pH-7 .5 , 50mM NaCl , and 50mM KCl .'}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 0), 'end':(9, 10), 'text':'Reactions were started by adding 100muM ATP ( final concentration )'}, {'start':(9, 11), 'end':(9, 30), 'text':'containing 0.1 muCi per muL of [ gamma 32 P ] - ATP in a total volume of 15muL .'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(10, 0), 'end':(10, 8), 'text':'This reaction was carried out for sixty minutes ,'}, {'start':(10, 9), 'end':(10, 24), 'text':'and was stopped by mixing 3mul of the reaction mixture with 3mul of 20mM EDTA .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 0), 'end':(11, 12), 'text':'Three microliters of this mixture was then spotted on a nitrocellulose membrane .'}, {'start':(12, 0), 'end':(12, 16), 'text':'The membrane was washed six times with a 1M NaCl and 1 % phosphoric acid solution .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'RightToLeft', 'children':[{'start':(13, 0), 'end':(13, 10), 'text':'After all washes the membrane was dried for one hour ,'}, {'start':(13, 11), 'end':(13, 24), 'text':'followed by a 5-20min exposure to a phosphor screen ( Molecular Dynamics ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(14, 0), 'end':(14, 12), 'text':'The spot intensity on the phosphor screen was imaged using a Typhoon phosphoimager'}, {'start':(14, 13), 'end':(14, 17), 'text':'( GE Healthcare ) .'}]}, {'start':(15, 0), 'end':(15, 10), 'text':'The intensity was quantitated using ImageQuant ( GE Healthcare ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(16, 0), 'end':(16, 2), 'text':'Deuterium Exchange Measurements'}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(17, 0), 'end':(17, 9), 'text':'Stock solutions of protein ( 30 pmol and mul )'}, {'label':'temporal', 'direction':'LeftToRight', 'children':[{'start':(17, 10), 'end':(17, 29), 'text':'were prepared in 20mM Tris pH-7 .2 , 50mM ammonium sulfate , 1 % ethylene glycol , and 5mM DTT'}, {'start':(17, 30), 'end':(17, 35), 'text':'following the procedure in the .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(18, 0), 'end':(18, 31), 'text':'Measurements in the presence of PDGFR pY were carried out by a 5-fold dilution of a 1mM PDGFR pY ( mouse PDGFR residues 735-767 , peptide sequence ESDGG ( pY ) MDMSKDESID'}, {'start':(18, 32), 'end':(18, 36), 'text':'( pY ) VPMLDMKGDIKYADIE )'}]}, {'start':(18, 37), 'end':(18, 37), 'text':'stock'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(18, 38), 'end':(18, 46), 'text':'in 10mM HEPES pH-7 .2 , 2 % DMSO'}, {'start':(18, 47), 'end':(18, 59), 'text':'giving a final concentration of 200muM PDGFR pY before addition of deuterium .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(19, 0), 'end':(19, 20), 'text':'Exchange reactions were initiated by the addition of 4mul of protein stock to 1mul of either PDGFR pY solution or blank'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(19, 21), 'end':(19, 26), 'text':'and allowed to equilibrate for 10min'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(19, 27), 'end':(19, 40), 'text':'followed by the addition of 25mul of a 98 % D 2 O solution'}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(19, 41), 'end':(19, 53), 'text':'containing 10mM HEPES pD-7 .2 , 50mM NaCl , and 2mM DTT ,'}, {'start':(19, 54), 'end':(19, 91), 'text':'giving a final concentration of 82 % D 2 O. Deuterium exchange reactions were allowed to carry on for five time points , 3 , 10 , 100 , 1000 , and 3000s of on-exchange at 23degreesC ,'}]}, {'start':(19, 92), 'end':(19, 97), 'text':'before addition of quench buffer .'}]}]}]}]}, {'start':(20, 0), 'end':(20, 22), 'text':'For 3s of on-exchange , an experiment was also performed at 0degreesC to examine exchange rates of extremely rapidly exchanging amide hydrogens .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(21, 0), 'end':(21, 9), 'text':'On-exchange was stopped by addition of 40mul of quench buffer'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(21, 10), 'end':(21, 19), 'text':'containing 1.2 % formic acid and 1.66 M Guanidine-HCl ,'}, {'start':(21, 20), 'end':(21, 26), 'text':'which lowered the pH to 2.6 .'}]}]}, {'start':(22, 0), 'end':(22, 11), 'text':'Samples were then immediately frozen in liquid nitrogen until mass analysis .'}]}]}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(23, 0), 'end':(23, 9), 'text':'Every time point and condition was a unique experiment ,'}, {'start':(23, 10), 'end':(23, 18), 'text':'and every DXMS experiment was repeated in duplicate .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(24, 0), 'end':(24, 30), 'text':'For DXMS studies on the K379E , Y685A , and double mutants , on-exchange experiments were carried out on the full length complexes of p110delta and p85alpha at two time points'}, {'start':(24, 31), 'end':(24, 36), 'text':'( 3 and 1000 s )'}]}, {'start':(24, 37), 'end':(24, 51), 'text':'that between them covered all time points with differences in exchange on nicSH2 binding .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(25, 0), 'end':(25, 12), 'text':'For lipid binding experiments , lipid vesicles were prepared at 5mg and ml'}, {'label':'joint', 'direction':'None', 'children':[{'start':(25, 13), 'end':(25, 15), 'text':'as described in'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(25, 16), 'end':(25, 27), 'text':'and were diluted 5-fold with a 98 % D 2 O solution'}, {'start':(25, 28), 'end':(25, 40), 'text':'containing 10mM HEPES pD-7 .2 , 50mM NaCl , and 2mM DTT .'}]}]}]}, {'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(26, 0), 'end':(26, 4), 'text':'Deuterium exchange reactions were started'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(26, 5), 'end':(26, 28), 'text':'by mixing 5mul of a protein stock solution ( 15 pmol and mul ) with 25mul of deuterated lipid buffer ( 25mug phospholipid )'}, {'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(26, 29), 'end':(26, 48), 'text':'giving a final solution of 65 % D 2 O. Half as much protein was used in lipid binding experiments'}, {'start':(26, 49), 'end':(26, 60), 'text':'to maximize the ratio of lipid to protein in the sample .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(27, 0), 'end':(27, 13), 'text':'Higher concentrations of protein or lipid in the sample led to sample aggregation .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(28, 0), 'end':(28, 6), 'text':'For this reason there was no chance'}, {'label':'background', 'direction':'LeftToRight', 'children':[{'start':(28, 7), 'end':(28, 25), 'text':'to preincubate the protein solution with lipid vesicles before addition of D 2 O due to aggregation of protein'}, {'start':(28, 26), 'end':(28, 34), 'text':'when combined with high levels of lipid vesicles .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(29, 0), 'end':(29, 34), 'text':'For AMPPNP binding experiments , protein was incubated with 10mM Mg 2+ and+ /- 5mM AMPPNP for 15min and then 5mul of the protein and nucleotide solution was diluted with 25mul of deuterated buffer .'}, {'start':(30, 0), 'end':(30, 6), 'text':'All other steps remained the same .'}]}]}]}]}, {'start':(31, 0), 'end':(31, 7), 'text':'Full experimental procedures are described in the .'}]}]}
1	12	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(0, 0), 'end':(0, 0), 'text':'Summary'}, {'start':(1, 0), 'end':(1, 8), 'text':'Phosphoinositide 3-kinase delta is upregulated in lymphocytic leukemias .'}]}, {'label':'textual-organization', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'RightToLeft', 'children':[{'start':(2, 0), 'end':(2, 10), 'text':'Because the p85-regulatory subunit binds to any class IA subunit ,'}, {'label':'contrast', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 11), 'end':(2, 19), 'text':'it was assumed there is a single universal p85'}, {'start':(2, 20), 'end':(2, 23), 'text':'mediated regulatory mechanism ;'}]}, {'start':(2, 24), 'end':(2, 33), 'text':'however , we find isozyme specific inhibition by p85alpha .'}]}]}, {'label':'background', 'direction':'RightToLeft', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 0), 'end':(3, 4), 'text':'Using deuterium exchange mass spectrometry'}, {'start':(3, 5), 'end':(3, 8), 'text':'( DXMS ) ,'}]}, {'start':(3, 9), 'end':(3, 17), 'text':'we mapped regulatory interactions of p110delta with p85alpha .'}]}]}, {'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(4, 0), 'end':(4, 15), 'text':'Both nSH2 and cSH2 domains of p85alpha contribute to full inhibition of p110delta , the nSH2'}, {'start':(4, 16), 'end':(4, 30), 'text':'by contacting the helical domain and the cSH2 via the C terminus of p110delta .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(5, 0), 'end':(5, 10), 'text':'The cSH2 inhibits p110beta and p110delta , but not p110alpha ,'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(5, 11), 'end':(5, 11), 'text':'implying'}, {'start':(5, 12), 'end':(5, 20), 'text':'that p110alpha is uniquely poised for oncogenic mutations .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 0), 'end':(6, 7), 'text':'Binding RTK phosphopeptides disengages the SH2 domains ,'}, {'start':(6, 8), 'end':(6, 15), 'text':'resulting in exposure of the catalytic subunit .'}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(7, 0), 'end':(7, 1), 'text':'We find'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(7, 2), 'end':(7, 14), 'text':'that phosphopeptides greatly increase the affinity of the heterodimer for PIP2 containing membranes'}, {'start':(7, 15), 'end':(7, 18), 'text':'measured by FRET .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 0), 'end':(8, 9), 'text':'DXMS identified regions decreasing exposure at membranes and also regions'}, {'start':(8, 10), 'end':(8, 12), 'text':'gaining exposure ,'}]}, {'start':(8, 13), 'end':(8, 22), 'text':'indicating loosening of interactions within the heterodimer at membranes .'}]}]}, {'start':(9, 0), 'end':(9, 0), 'text':'Highlights'}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(10, 0), 'end':(10, 9), 'text':'> Both nSH2 and cSH2 of p85alpha inhibit p110delta ,'}, {'start':(10, 10), 'end':(10, 43), 'text':'and pY peptides or mutations activate > DXMS mapped dynamic changes in free p110delta and p110delta and p85 with and without pY peptides > pY peptide increases p110delta and p85 affinity for lipids ;'}]}, {'start':(10, 44), 'end':(10, 62), 'text':'interactions were mapped by DXMS > cSH2 point mutation in p85alpha activates p110delta and p110beta , but not p110alpha'}]}]}]}
48	170	{'label':'topic-change', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(0, 0), 'end':(0, 0), 'text':'Results'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(1, 0), 'end':(1, 10), 'text':'The cSH2 of p85alpha Plays an Important Regulatory Role for p110delta'}, {'label':'joint', 'direction':'None', 'children':[{'start':(2, 0), 'end':(2, 12), 'text':'The regulation of p110alpha by p85 has been thoroughly studied ( ) ,'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(2, 13), 'end':(2, 17), 'text':'and it has been assumed'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 18), 'end':(2, 30), 'text':'that the same mechanism of regulation would govern all class IA enzymes ,'}, {'start':(2, 31), 'end':(2, 33), 'text':'including p110delta .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'enablement', 'direction':'RightToLeft', 'children':[{'start':(3, 0), 'end':(3, 4), 'text':'To examine this assumption ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 5), 'end':(3, 12), 'text':'we first performed lipid kinase assays to test'}, {'start':(3, 13), 'end':(3, 28), 'text':'which of the domains of p85alpha contribute to inhibition of the basal activity of p110delta .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 0), 'end':(4, 5), 'text':'For the assays we used vesicles'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 6), 'end':(4, 15), 'text':'containing 5 % PIP2 and a defined mixture of lipids'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 16), 'end':(4, 39), 'text':'mimicking natural membranes ( 20 % PS and 45 % PE and 15 % PC and 10 % cholesterol and 5 % sphingomyelin )'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 40), 'end':(4, 45), 'text':'similar in composition to previous studies'}, {'start':(4, 46), 'end':(4, 52), 'text':'examining plasma membrane interactions ( ) .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(5, 0), 'end':(5, 10), 'text':'We used several truncated variants of the p85alpha regulatory subunit :'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(5, 11), 'end':(5, 16), 'text':'iSH2 ( residues 434-600 ) ,'}, {'start':(5, 17), 'end':(5, 23), 'text':'which has only the iSH2 domain ;'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(5, 24), 'end':(5, 24), 'text':'niSH2'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(5, 25), 'end':(5, 29), 'text':'( residues 322-600 ) ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(5, 30), 'end':(5, 45), 'text':'which has both the nSH2 and iSH2 domains ; and nicSH2 ( residues 322-724 ) ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(5, 46), 'end':(5, 55), 'text':'which has the nSH2 , iSH2 , and cSH2 domains'}, {'start':(5, 56), 'end':(5, 61), 'text':'( A ; A ) .'}]}]}]}]}]}]}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(6, 0), 'end':(6, 4), 'text':'The regulatory subunits were coexpressed'}, {'start':(6, 5), 'end':(6, 14), 'text':'and copurified with the full length p110delta catalytic subunit .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'cause', 'direction':'LeftToRight', 'children':[{'label':'enablement', 'direction':'RightToLeft', 'children':[{'start':(7, 0), 'end':(7, 8), 'text':'To express the catalytic subunit free froma regulatory subunit'}, {'start':(7, 9), 'end':(7, 20), 'text':'we used the DeltaABD-p110delta construct ( DeltaABD-p110delta , residues 106-1044 ) ,'}]}, {'start':(7, 21), 'end':(7, 36), 'text':'because the full-length p110delta in the absence of a regulatory subunit is insoluble ( ) .'}]}, {'label':'comparison', 'direction':'LeftToRight', 'children':[{'start':(8, 0), 'end':(8, 6), 'text':'DeltaABD-p110delta had a ~ 2.5-fold higher activity'}, {'start':(8, 7), 'end':(8, 14), 'text':'compared to p110delta+ iSH2 ( B ) .'}]}]}, {'label':'contrast', 'direction':'RightToLeft', 'children':[{'start':(9, 0), 'end':(9, 15), 'text':'Because both the ABD domain and iSH2 domain are in contact with the kinase domain ,'}, {'start':(9, 16), 'end':(9, 27), 'text':'either could be inhibiting PI3K activity in the p110delta+ iSH2 complex .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'RightToLeft', 'children':[{'label':'comparison', 'direction':'LeftToRight', 'children':[{'start':(10, 0), 'end':(10, 8), 'text':'The p110delta+ niSH2 complex was inhibited only ~ 5-fold'}, {'start':(10, 9), 'end':(10, 16), 'text':'compared to p110delta+ iSH2 ( C ) .'}]}, {'label':'cause', 'direction':'LeftToRight', 'children':[{'start':(11, 0), 'end':(11, 14), 'text':'However , the p110delta+ nicSH2 complex was inhibited ~ 15-fold compared to p110delta+ iSH2 ,'}, {'start':(11, 15), 'end':(11, 25), 'text':'making it significantly less active than the p110delta+ niSH2 complex .'}]}]}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(12, 0), 'end':(12, 16), 'text':'The inhibition of p110delta by the cSH2 domain , in the context of the nicSH2 construct ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(12, 17), 'end':(12, 26), 'text':'stands in sharp contrast with previous studies on p110alpha ,'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(12, 27), 'end':(12, 28), 'text':'which showed'}, {'label':'joint', 'direction':'None', 'children':[{'start':(12, 29), 'end':(12, 40), 'text':'that the minimal construct necessary for full inhibition was the niSH2 ,'}, {'label':'contrast', 'direction':'LeftToRight', 'children':[{'start':(12, 41), 'end':(12, 53), 'text':'and that the cSH2 does not inhibit the basal activity of p110alpha ,'}, {'start':(12, 54), 'end':(12, 82), 'text':'even though it was shown to be necessary for full activation by a pY peptide ( from IRS-1 ) in the context of full length p85 ( ) .'}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(13, 0), 'end':(13, 2), 'text':'We also tested'}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(13, 3), 'end':(13, 8), 'text':'if the presence of PDGFR bis'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(13, 9), 'end':(13, 11), 'text':'phosphorylated pY peptide'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(13, 12), 'end':(13, 13), 'text':'( residues'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(13, 14), 'end':(13, 20), 'text':'735-767 , with pY740 and pY751 ,'}, {'start':(13, 21), 'end':(13, 27), 'text':'referred to afterwards as PDGFR pY )'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(13, 28), 'end':(13, 30), 'text':'can relieve inhibition'}, {'start':(13, 31), 'end':(13, 39), 'text':'imposed by both the nSH2 and cSH2 domains .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(14, 0), 'end':(14, 3), 'text':'Indeed , we found'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(14, 4), 'end':(14, 20), 'text':'that the presence of PDGFR pY does fully relieve inhibition from both the nSH2 and cSH2 ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(14, 21), 'end':(14, 28), 'text':'which brings the enzyme activity for all iSH2'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(14, 29), 'end':(14, 44), 'text':'containing complexes to a similar activated level , close to the activity of the p110delta+ iSH2'}, {'start':(14, 45), 'end':(14, 48), 'text':'( C ) .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(15, 0), 'end':(15, 7), 'text':'The highest activation occurred with the nicSH2 ,'}, {'start':(15, 8), 'end':(15, 17), 'text':'which was activated ~ 13-fold by the PDGFR pY .'}]}, {'start':(16, 0), 'end':(16, 14), 'text':'The fold of activation is critically dependent on the nature of the lipid substrate .'}]}]}]}]}]}, {'label':'topic-change', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(17, 0), 'end':(17, 3), 'text':'However , the activation'}, {'start':(17, 4), 'end':(17, 5), 'text':'we see'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(17, 6), 'end':(17, 20), 'text':'is in line with studies on purified full length p110delta and p85alpha complex on PIP2'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(17, 21), 'end':(17, 23), 'text':'containing lipid vesicles'}, {'start':(17, 24), 'end':(17, 36), 'text':'showing a 20-40-fold activation on addition of a pY peptide ( ) .'}]}]}]}, {'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(18, 0), 'end':(18, 4), 'text':'We carried out DXMS experiments'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(18, 5), 'end':(18, 10), 'text':'to detect changes in protein dynamics'}, {'start':(18, 11), 'end':(18, 33), 'text':'that might explain inhibition by both the nSH2 and cSH2 domains of the regulatory subunit , and activation by PDGFR pY binding .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(19, 0), 'end':(19, 13), 'text':'Digestion of p110delta and p85alpha Constructs and Global Deuterium Exchange of p110delta and p85alpha'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(20, 0), 'end':(20, 18), 'text':'The optimized peptide digestion map of the p110delta ( B ) was composed of 116 individual peptic peptides ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(20, 19), 'end':(20, 30), 'text':'covering ~ 83 % of the sequence of the catalytic subunit ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(20, 31), 'end':(20, 44), 'text':'whereas the map of the p85alpha nicSH2 regulatory subunit consisted of 53 peptides ,'}, {'start':(20, 45), 'end':(20, 56), 'text':'covering ~ 85 % of the sequence of the regulatory subunit .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(21, 0), 'end':(21, 9), 'text':'Four different enzyme complexes were studied by deuterium exchange :'}, {'start':(21, 10), 'end':(21, 32), 'text':'p110delta+ p85alpha nicSH2 in the presence and absence of PDGFR pY , p110delta+ p85alpha iSH2 , and p110delta alone ( DeltaABD-p110delta ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(22, 0), 'end':(22, 16), 'text':'No experiments were performed on the DeltaABD-p110delta in the presence of p85alpha constructs due to previous work'}, {'start':(22, 17), 'end':(22, 31), 'text':'showing no detectable binding of p85 by p110 without the ABD domain ( ) .'}]}]}]}]}, {'start':(23, 0), 'end':(23, 10), 'text':'All heterodimers had an equal ratio of p110 and p85 .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(24, 0), 'end':(24, 20), 'text':'The global exchange profile of DeltaABD-p110delta is shown modeled onto the recently solved crystal structure of the p110delta catalytic subunit .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(25, 0), 'end':(25, 16), 'text':'The global exchange profile of the p85alpha nicSH2 was modeled onto the structures of the isolated nSH2'}, {'start':(25, 17), 'end':(25, 20), 'text':'( residues 323-432 )'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(25, 21), 'end':(25, 23), 'text':'and isolated cSH2'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(25, 24), 'end':(25, 38), 'text':'( residues 613-720 ) domains in complexes with PDGFR-pY , and onto the isolated iSH2'}, {'start':(25, 39), 'end':(25, 43), 'text':'( residues 431-600 ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(26, 0), 'end':(26, 10), 'text':'Differences in Exchange of p85alpha in the Presence of PDGFR pY'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(27, 0), 'end':(27, 7), 'text':'Differences in exchange rates for the p85alpha nicSH2'}, {'start':(27, 8), 'end':(27, 38), 'text':'( bound to p110delta ) in the presence and absence of a PDGFR pY were mapped onto the crystal structures of the nSH2 , iSH2 , and cSH2 of p85alpha .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(28, 0), 'end':(28, 11), 'text':'It is important to note that many of the deuterium exchange differences'}, {'start':(28, 12), 'end':(28, 19), 'text':'caused by p85alpha constructs and PDGFR pY binding'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(28, 20), 'end':(28, 33), 'text':'mapped on the crystal structures are on the order of 1.0 Da within peptides'}, {'start':(28, 34), 'end':(28, 40), 'text':'that can incorporate > 10 deuterons .'}]}]}]}]}]}, {'label':'topic-change', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(29, 0), 'end':(29, 3), 'text':'Without sufficient overlapping peptides'}, {'start':(29, 4), 'end':(29, 15), 'text':'it is impossible to precisely locate the position of these changes .'}]}, {'label':'contrast', 'direction':'RightToLeft', 'children':[{'start':(30, 0), 'end':(30, 9), 'text':'Although peptides with changes are colored in all figures ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(30, 10), 'end':(30, 12), 'text':'it is possible'}, {'start':(30, 13), 'end':(30, 24), 'text':'that only one to two amides in these regions are affected .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'explanation', 'direction':'LeftToRight', 'children':[{'start':(31, 0), 'end':(31, 17), 'text':'The nSH2 and cSH2 domains showed nearly global decreases in exchange in the presence of PDGFR pY .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(32, 0), 'end':(32, 5), 'text':'This agrees with previous DXMS work'}, {'start':(32, 6), 'end':(32, 22), 'text':'that shows global decreases in exchange for isolated SH2 domains bound to pY peptides ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(33, 0), 'end':(33, 7), 'text':'We were most interested in looking for peptides'}, {'label':'comparison', 'direction':'LeftToRight', 'children':[{'start':(33, 8), 'end':(33, 19), 'text':'that have increases in exchange in the presence of PDGFR pY ,'}, {'start':(33, 20), 'end':(33, 30), 'text':'as these might indicate interfacial regions between p110delta and p85alpha .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'start':(34, 0), 'end':(34, 16), 'text':'Two p85alpha peptides , 444-456 in the beginning of the iSH2 and 681-687 in the cSH2 ,'}, {'start':(34, 17), 'end':(34, 27), 'text':'showed increases in exchange in the presence of PDGFR pY .'}]}, {'start':(35, 0), 'end':(35, 19), 'text':'Peptide 444-456 also showed an increase in exchange in the p110delta+ iSH2 complex in comparison with the p110delta+ nicSH2 .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(36, 0), 'end':(36, 8), 'text':'An increase in exchange was also seen with peptides'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(36, 9), 'end':(36, 15), 'text':'spanning the C-terminal end of the iSH2'}, {'start':(36, 16), 'end':(36, 28), 'text':'( 546-581 ) in the absence of the nSH2 and cSH2 domains ,'}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(36, 29), 'end':(36, 29), 'text':'suggesting'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(36, 30), 'end':(36, 45), 'text':'that the coiled-coil becomes more protected from exchange in the presence of these two SH2 domains'}, {'start':(36, 46), 'end':(36, 49), 'text':'( B ) .'}]}]}]}, {'start':(37, 0), 'end':(37, 21), 'text':'Peptide 681-687 in the cSH2 also showed an increase in exchange ( 1.0 Da ) in the presence of PDGFR pY .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(38, 0), 'end':(38, 1), 'text':'We hypothesized'}, {'label':'joint', 'direction':'None', 'children':[{'start':(38, 2), 'end':(38, 15), 'text':'that this region in the cSH2 might form a contact surface for p110delta ,'}, {'start':(38, 16), 'end':(38, 28), 'text':'and that this interaction is broken in the presence of PDGFR pY .'}]}]}, {'start':(39, 0), 'end':(39, 16), 'text':'No region on the nSH2 had an increase in exchange in the presence of PDGFR pY .'}]}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(40, 0), 'end':(40, 4), 'text':'We would like to emphasize'}, {'label':'condition', 'direction':'LeftToRight', 'children':[{'start':(40, 5), 'end':(40, 12), 'text':'that no change in exchange would be expected'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(40, 13), 'end':(40, 20), 'text':'if the PDGFR pY protects the same regions'}, {'start':(40, 21), 'end':(40, 32), 'text':'as are protected by p110delta in the absence of PDGFR pY .'}]}]}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(41, 0), 'end':(41, 6), 'text':'Previous crystallographic work on p110alpha would predict'}, {'start':(41, 7), 'end':(41, 18), 'text':'that this is exactly the case for the nSH2 ( ) .'}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(42, 0), 'end':(42, 1), 'text':'We find'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(42, 2), 'end':(42, 13), 'text':'that the cSH2 showed an increase in exchange on PDGFR pY binding'}, {'start':(42, 14), 'end':(42, 18), 'text':'( region 681-687 ) ,'}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(42, 19), 'end':(42, 19), 'text':'suggesting'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(42, 20), 'end':(42, 46), 'text':'that the PDGFR pY binding surface of the cSH2 and the inhibitory contact surface with p110 do not completely coincide , in contrast to the nSH2 ,'}, {'start':(42, 47), 'end':(42, 50), 'text':'where they do .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(43, 0), 'end':(43, 12), 'text':'Differences in Exchange of p110delta in the Presence of p85alpha and PDGFR pY'}, {'label':'enablement', 'direction':'RightToLeft', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(44, 0), 'end':(44, 7), 'text':'To gain an insight into regions on p110delta'}, {'start':(44, 8), 'end':(44, 16), 'text':'that are in contact with the p85 subunit ,'}]}, {'start':(44, 17), 'end':(44, 31), 'text':'we determined differences in exchange rates for p110delta in the presence of p85alpha constructs .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(45, 0), 'end':(45, 12), 'text':'Distinct regions in p110delta showed differences in exchange between the free catalytic subunit'}, {'start':(45, 13), 'end':(45, 15), 'text':'( DeltaABD-p110delta )'}]}, {'start':(45, 16), 'end':(45, 28), 'text':'and p110delta bound to the nicSH2 of p85alpha ( A ; ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(46, 0), 'end':(46, 20), 'text':'By comparing the exchange differences between the p110delta+ iSH2 complex and the p110delta+ nicSH2 complex we were able to localize changes'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(46, 21), 'end':(46, 30), 'text':'caused by binding to the iSH2 domain , and changes'}, {'start':(46, 31), 'end':(46, 40), 'text':'that were caused by the nSH2 and cSH2 domains .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(47, 0), 'end':(47, 2), 'text':'Differences in Exchange'}, {'start':(47, 3), 'end':(47, 6), 'text':'Caused by the iSH2'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(48, 0), 'end':(48, 16), 'text':'Four regions of p110delta showed decreases in exchange between the DeltaABD-p110delta and the p110delta+ iSH2 complex :'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(48, 17), 'end':(48, 47), 'text':'120-138 ( in the linker between the ABD and RBD ) , 327-337 and 453-468 ( C2 domain ) , and 698-713 ( in the N-lobe of the kinase domain )'}, {'start':(48, 48), 'end':(48, 52), 'text':'( A ; ) .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(49, 0), 'end':(49, 12), 'text':'The region 120-138 is located near the interface with the ABD domain ,'}, {'start':(49, 13), 'end':(49, 27), 'text':'and the change in deuteration is most likely the consequence of the ABD deletion .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(50, 0), 'end':(50, 16), 'text':'Peptides 327-337 , 453-468 , and 698-713 of p110delta are all located at or near the crevice'}, {'start':(50, 17), 'end':(50, 30), 'text':'where the iSH2 domain binds in the p110alpha and iSH2 structure ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(51, 0), 'end':(51, 10), 'text':'There was also a slight decrease in exchange in peptide 920-935'}, {'start':(51, 11), 'end':(51, 16), 'text':'spanning the substrate binding loop .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(52, 0), 'end':(52, 2), 'text':'Helical Domain Changes'}, {'start':(52, 3), 'end':(52, 8), 'text':'Caused by nicSH2 and PDGFR pY'}]}, {'label':'comparison', 'direction':'LeftToRight', 'children':[{'start':(53, 0), 'end':(53, 14), 'text':'Several distinct peptides showed decreases in exchange in the presence of the p110delta+ nicSH2 complex'}, {'start':(53, 15), 'end':(53, 21), 'text':'compared to the p110delta+ iSH2 complex .'}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(54, 0), 'end':(54, 12), 'text':'One of these peptides , 524-529 , is located in the helical domain'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(54, 13), 'end':(54, 18), 'text':'and showed a decrease in exchange'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(54, 19), 'end':(54, 23), 'text':'( > 1.0 Da )'}, {'start':(54, 24), 'end':(54, 27), 'text':'( A ) .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(55, 0), 'end':(55, 10), 'text':'This peptide contains E525 , equivalent to E545 in p110alpha ,'}, {'start':(55, 11), 'end':(55, 29), 'text':'which has been shown biochemically ( ) and structurally ( ) to be important in binding the nSH2 .'}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(56, 0), 'end':(56, 15), 'text':'Experiments were also carried out with the p110delta+ nicSH2 complex in the presence of PDGFR pY'}, {'start':(56, 16), 'end':(56, 19), 'text':'( B ) .'}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(57, 0), 'end':(57, 19), 'text':'The presence of PDGFR pY exposed this region to exchange to the same extent as the free catalytic domain ,'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(57, 20), 'end':(57, 20), 'text':'suggesting'}, {'start':(57, 21), 'end':(57, 33), 'text':'that PDGFR pY binding breaks the contacts between the nSH2 and p110delta .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(58, 0), 'end':(58, 7), 'text':'This is consistent with our lipid kinase assays'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(58, 8), 'end':(58, 8), 'text':'showing'}, {'start':(58, 9), 'end':(58, 29), 'text':'that the presence of PDGFR pY activates the p110delta+ niSH2 complex to the same level as the p110delta+ iSH2 complex ,'}]}]}, {'start':(58, 30), 'end':(58, 39), 'text':'and agrees with previous results for p110alpha ( ) .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(59, 0), 'end':(59, 2), 'text':'Kinase Domain Changes'}, {'start':(59, 3), 'end':(59, 8), 'text':'Caused by nicSH2 and PDGFR pY'}]}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(60, 0), 'end':(60, 0), 'text':'Peptides'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(60, 1), 'end':(60, 5), 'text':'spanning the substrate binding loop'}, {'start':(60, 6), 'end':(60, 16), 'text':'( 920-935 ) and the C-terminal end of the kinase domain'}]}, {'label':'comparison', 'direction':'LeftToRight', 'children':[{'start':(60, 17), 'end':(60, 37), 'text':'( 1010-1019 , 1020-1022 , and 1023-1033 ) also showed decreases in exchange in the presence of the p110delta+ nicSH2 complex'}, {'start':(60, 38), 'end':(60, 47), 'text':'compared to the p110delta+ iSH2 complex ( A ) .'}]}]}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(61, 0), 'end':(61, 16), 'text':'None of these peptides are near the nSH2 contact site with the catalytic domain of p110alpha ,'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(61, 17), 'end':(61, 19), 'text':'and we postulate'}, {'start':(61, 20), 'end':(61, 32), 'text':'that they may form a contact site for the cSH2 in p110delta .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(62, 0), 'end':(62, 32), 'text':'The largest decrease in exchange ( 2.0 Da ) was in the peptide from 1023-1033 , but only at early time points , with no changes in exchange after 100s of on-exchange .'}, {'label':'explanation', 'direction':'LeftToRight', 'children':[{'start':(63, 0), 'end':(63, 8), 'text':'These changes were equally distributed through this region ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(63, 9), 'end':(63, 15), 'text':'because peptides 1023-1027 and 1028-1033 showed decreases'}, {'start':(63, 16), 'end':(63, 25), 'text':'( > 0.7 Da ) in exchange ( ) .'}]}]}]}, {'label':'contrast', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(64, 0), 'end':(64, 10), 'text':'This region spans the end of helix kalpha11 and six residues'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(64, 11), 'end':(64, 14), 'text':'following this helix ,'}, {'start':(64, 15), 'end':(64, 23), 'text':'which are disordered in the structure of p110delta .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(65, 0), 'end':(65, 13), 'text':'This area forms the " elbow " in p110gamma and class III Vps34 isoforms'}, {'start':(65, 14), 'end':(65, 25), 'text':'that connects the two C-terminal helices kalpha11 and kalpha12 ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(66, 0), 'end':(66, 4), 'text':'It has been recently shown'}, {'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(66, 5), 'end':(66, 19), 'text':'that deletion of the kalpha12 in Vps34 abolishes the lipid kinase activity ( ) ,'}, {'start':(66, 20), 'end':(66, 36), 'text':'so we tested an analogous deletion for p110delta and p85alpha nicSH2 ( Delta1028-1044 in p110delta ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(67, 0), 'end':(67, 7), 'text':'This deletion completely abolishes p110delta lipid kinase activity'}, {'start':(67, 8), 'end':(67, 11), 'text':'( C ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(68, 0), 'end':(68, 5), 'text':'Therefore , the DXMS experiments show'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(68, 6), 'end':(68, 19), 'text':'that this region critical for catalysis has one of the largest decreases in exposure'}, {'start':(68, 20), 'end':(68, 23), 'text':'caused by nicSH2 .'}]}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(69, 0), 'end':(69, 1), 'text':'Peptide 920-935'}, {'start':(69, 2), 'end':(69, 11), 'text':'that spans the distal half of the substrate binding loop'}]}, {'start':(69, 12), 'end':(69, 17), 'text':'( residues 911-36 in p110delta )'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(69, 18), 'end':(69, 22), 'text':'showed a decrease in exchange'}, {'start':(69, 23), 'end':(69, 28), 'text':'( > 1.5 Da ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(70, 0), 'end':(70, 33), 'text':'The presence of PDGFR pY exposed this peptide as well as the C-terminal peptides 1020-1022 and 1023-1033 in p110delta+ nicSH2 ( B ) to the same extent as in the p110delta+ iSH2 complex .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(71, 0), 'end':(71, 15), 'text':'The changes in deuterium exchange for these regions correlated very well with our activity results :'}, {'start':(71, 16), 'end':(71, 39), 'text':'addition of PDGFR pY to the p110delta+ nicSH2 complex resulted in activity and deuteration levels similar to that of the p110delta+ iSH2 complex .'}]}, {'label':'background', 'direction':'LeftToRight', 'children':[{'start':(72, 0), 'end':(72, 17), 'text':'One peptide in the kinase domain , 939-958 , only showed decreases in exchange ( 0.5 Da )'}, {'start':(72, 18), 'end':(72, 24), 'text':'when comparing p110delta+ nicSH2 to DeltaABD-p110delta .'}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(73, 0), 'end':(73, 8), 'text':'This region is located adjacent to the C-terminal helix'}, {'start':(73, 9), 'end':(73, 18), 'text':'and may form another contact surface for the cSH2 .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'RightToLeft', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(74, 0), 'end':(74, 9), 'text':'PDGFR pY Increases p110delta and p85alpha Affinity for Membrane Binding'}, {'label':'background', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(75, 0), 'end':(75, 17), 'text':'To understand the PI3K activation by PDGFR pY binding we examined the affinity of p110delta for lipid membranes'}, {'start':(75, 18), 'end':(75, 20), 'text':'using protein-lipid FRET'}]}, {'start':(75, 21), 'end':(75, 31), 'text':'as applied previously to examine Vps34 lipid interactions ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(76, 0), 'end':(76, 52), 'text':'Two different types of lipid vesicles were examined , one with 5 % PIP2 present ( 20 % PS and 10 % Dansyl PS , 35 % PE and 15 % PC and 10 % cholesterol , 5 % sphingomyelin , 5 % PIP2 ) , and one with 0 % PIP2 ,'}, {'start':(76, 53), 'end':(76, 59), 'text':'where PIP2 was replaced by PS .'}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(77, 0), 'end':(77, 2), 'text':'These experiments showed'}, {'start':(77, 3), 'end':(77, 20), 'text':'that the p110delta and p85alpha complex had very low lipid binding in the absence of PDGFR pY .'}]}]}, {'start':(78, 0), 'end':(78, 24), 'text':'However , in the presence of PDGFR pY , the p110delta and p85alpha complex bound PIP2 containing vesicles with much higher affinity ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(79, 0), 'end':(79, 3), 'text':'The DeltaABD-p110delta construct ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(79, 4), 'end':(79, 10), 'text':'which is devoid of any inhibitory contacts'}, {'start':(79, 11), 'end':(79, 21), 'text':'imposed by p85 ( as well as lacking ABD ) ,'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(79, 22), 'end':(79, 24), 'text':'bound to PIP2'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(79, 25), 'end':(79, 30), 'text':'containing membranes with high affinity ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(79, 31), 'end':(79, 35), 'text':'similarly to the PDGFR pY'}, {'start':(79, 36), 'end':(79, 42), 'text':'activated p110delta and p85alpha ( ) .'}]}]}]}]}, {'start':(80, 0), 'end':(80, 14), 'text':'The presence of PDGFR pY had no effect on lipid binding of the DeltaABD-p110delta .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'explanation', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'start':(81, 0), 'end':(81, 3), 'text':'Binding to lipid vesicles'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(81, 4), 'end':(81, 13), 'text':'containing 5 % PIP2 was more efficient compared to vesicles'}, {'start':(81, 14), 'end':(81, 16), 'text':'lacking PIP2 ,'}]}]}, {'start':(81, 17), 'end':(81, 32), 'text':'for both the free catalytic subunit and the PDGFR pY activated p110delta and p85alpha construct .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(82, 0), 'end':(82, 17), 'text':'The PDGFR pY activation of p110delta and p85alpha also caused a small increase in binding to lipid vesicles'}, {'start':(82, 18), 'end':(82, 20), 'text':'lacking PIP2 ,'}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(82, 21), 'end':(82, 21), 'text':'showing'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(82, 22), 'end':(82, 29), 'text':'that PIP2 substrate is not the only component'}, {'start':(82, 30), 'end':(82, 36), 'text':'involved in PI3K binding to membranes .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(83, 0), 'end':(83, 2), 'text':'Changes in Exchange'}, {'start':(83, 3), 'end':(83, 8), 'text':'Caused by Interaction with Lipid Vesicles'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(84, 0), 'end':(84, 9), 'text':'PI3K must access its substrate at the lipid interface ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(84, 10), 'end':(84, 15), 'text':'and understanding changes in protein dynamics'}, {'start':(84, 16), 'end':(84, 29), 'text':'on binding the lipid interface is important for understanding the mechanism of regulation .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(85, 0), 'end':(85, 39), 'text':'Toward this end , we performed deuterium exchange experiments at three time points ( 3 , 30 , and 300 s ) with a PDGFR pY activated complex of p110delta+ nicSH2 in the presence and absence of 5 % PIP2'}, {'start':(85, 40), 'end':(85, 43), 'text':'containing lipid vesicles .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(86, 0), 'end':(86, 12), 'text':'These experiments were carried out in the absence of Mg 2+ and ATP'}, {'start':(86, 13), 'end':(86, 17), 'text':'to prevent enzyme activity .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(87, 0), 'end':(87, 36), 'text':'Several distinct regions in p110delta ( 698-715 , 850-856 , 908-919 , 920-935 , 939-958 , 982-989 , and 1024-1033 ) and p85alpha ( 414-420 ) had decreases in exchange in the presence of lipid substrate .'}, {'label':'joint', 'direction':'None', 'children':[{'start':(88, 0), 'end':(88, 12), 'text':'Regions 698-715 spanning the loop between kalpha1 and kalpha2 in the kinase domain'}, {'start':(88, 13), 'end':(88, 35), 'text':'and 850-856 covering kalpha5 and the loop between kalpha4 and kalpha5 were both previously proposed to participate in membrane binding ( ) .'}]}]}]}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(89, 0), 'end':(89, 9), 'text':'Region 908-919 containing the beginning of the substrate binding loop'}, {'start':(89, 10), 'end':(89, 15), 'text':'( encompassing the DFG motif )'}]}, {'start':(89, 16), 'end':(89, 28), 'text':'also had a decrease in exchange in the presence of lipid vesicles .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(90, 0), 'end':(90, 12), 'text':'Region 982-989 is adjacent to the substrate binding loop in the structure .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(91, 0), 'end':(91, 7), 'text':'It contains part of kalpha9 and the loop'}, {'start':(91, 8), 'end':(91, 11), 'text':'connecting to kalpha10 .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(92, 0), 'end':(92, 18), 'text':'The p110alpha helix equivalent to p110delta helix kalpha10 is known to interact with the nSH2 domain ( ) .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(93, 0), 'end':(93, 17), 'text':'Region 1024-1033 at the C-terminal end of p110delta is equivalent to the C-terminal tail of class III PI3Ks'}, {'start':(93, 18), 'end':(93, 26), 'text':'that was shown to bind membranes ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(94, 0), 'end':(94, 17), 'text':'Interestingly , regions 920-935 , 939-958 , and 1024-1033 were all protected by the presence of the nicSH2'}, {'start':(94, 18), 'end':(94, 27), 'text':'and also all show an interaction with lipid vesicles ,'}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(94, 28), 'end':(94, 28), 'text':'suggesting'}, {'start':(94, 29), 'end':(94, 39), 'text':'that p85 greatly regulates the interaction of p110 with membranes .'}]}]}, {'label':'evaluation', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(95, 0), 'end':(95, 5), 'text':'Surprisingly , we find some regions'}, {'start':(95, 6), 'end':(95, 18), 'text':'that have an increase in exchange in the presence of lipid vesicles .'}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(96, 0), 'end':(96, 7), 'text':'One is in p110delta , region 71-91 ,'}, {'start':(96, 8), 'end':(96, 14), 'text':'which is in the ABD domain ,'}]}, {'start':(96, 15), 'end':(96, 32), 'text':'and the other two are in the iSH2 domain of p85alpha ( regions 467-476 and 556-570 ) .'}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(97, 0), 'end':(97, 1), 'text':'This indicates'}, {'start':(97, 2), 'end':(97, 18), 'text':'that the presence of lipid vesicles may loosen the interaction between the iSH2 and the p110delta .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(98, 0), 'end':(98, 20), 'text':'Experiments were also performed on the full length p110delta and p85alpha complex in the presence of PDGFR pY and 10mM Mg'}, {'start':(98, 21), 'end':(98, 38), 'text':'2+ with and without 5mM nonhydrolysable ATP analog , AMPPNP to examine possible changes on nucleotide binding .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(99, 0), 'end':(99, 15), 'text':'No changes were seen in the catalytic subunit on AMPPNP and Mg 2+ binding ( data'}, {'start':(99, 16), 'end':(99, 19), 'text':'not shown ) .'}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(100, 0), 'end':(100, 5), 'text':'This is not surprising because peptides'}, {'label':'textual-organization', 'direction':'None', 'children':[{'start':(100, 6), 'end':(100, 24), 'text':'spanning the ATP binding pocket ( 752-762 , 886-900 ) experience < 25 % exchange even at 3000 s.'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(101, 0), 'end':(101, 2), 'text':'Engineering p85alpha Mutations'}, {'start':(101, 3), 'end':(101, 5), 'text':'that Activate p110delta'}]}, {'start':(102, 0), 'end':(102, 16), 'text':'DXMS identified the region from 681-687 in the cSH2 as part of the interface with p110delta .'}]}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(103, 0), 'end':(103, 1), 'text':'We hypothesized'}, {'label':'background', 'direction':'LeftToRight', 'children':[{'start':(103, 2), 'end':(103, 22), 'text':'that the cSH2 may be responsible for the observed changes in exposure of the C-terminal end of the p110delta kinase domain'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(103, 23), 'end':(103, 28), 'text':'when p110delta is bound to nicSH2'}, {'start':(103, 29), 'end':(103, 33), 'text':'compared to free p110delta .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'LeftToRight', 'children':[{'start':(104, 0), 'end':(104, 4), 'text':'To test this hypothesis ,'}, {'start':(104, 5), 'end':(104, 14), 'text':'we mutated Tyr-685 in the p85alpha cSH2 to alanine .'}]}, {'start':(105, 0), 'end':(105, 27), 'text':'The p110delta+ nicSH2 Y685A mutant complex showed higher basal activity than the equivalent wild and type complex and the same basal activity as the p110delta+ niSH2 complex .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(106, 0), 'end':(106, 21), 'text':'In the presence of PDGFR pY , the mutant complex was activated to a similar level as the niSH2 and nicSH2 complexes'}, {'start':(106, 22), 'end':(106, 25), 'text':'( C ) .'}]}, {'label':'enablement', 'direction':'RightToLeft', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(107, 0), 'end':(107, 1), 'text':'To examine'}, {'start':(107, 2), 'end':(107, 32), 'text':'if this mutation was functionally important in the regulation of the full length p110delta and p85alpha complex , as well as to determine individual effects of the nSH2 and cSH2 ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(107, 33), 'end':(107, 37), 'text':'we purified full length complexes'}, {'start':(107, 38), 'end':(107, 56), 'text':'containing the K379E nSH2 mutation , the Y685A cSH2 mutation , and the double mutant K379E , Y685A .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(108, 0), 'end':(108, 19), 'text':'The engineered oncogenic K379E mutation in nSH2 has been previously shown to activate p110alpha both invitro and invivo ( )'}, {'start':(108, 20), 'end':(108, 31), 'text':'by breaking the contact between the nSH2 and the helical domain .'}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(109, 0), 'end':(109, 2), 'text':'Enzyme activity assays'}, {'start':(109, 3), 'end':(109, 9), 'text':'performed with 5 % PIP2 liposomes showed'}]}, {'start':(109, 10), 'end':(109, 28), 'text':'that the K379E or Y685A p85 mutations activate the enzyme 10-fold and 5-fold , respectively ( A ) ,'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(109, 29), 'end':(109, 40), 'text':'and that the presence of both mutations fully activated the enzyme ,'}, {'start':(109, 41), 'end':(109, 50), 'text':'and made it insensitive to further PDGFR pY activation .'}]}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(110, 0), 'end':(110, 17), 'text':'Deuterium exchange experiments were then carried out on the K379E , Y685A , and double mutant complexes .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(111, 0), 'end':(111, 6), 'text':'Both of these mutations maintained the ability'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(111, 7), 'end':(111, 10), 'text':'to bind PDGFR pY'}, {'start':(111, 11), 'end':(111, 37), 'text':'as shown by similar decreases in exchange in peptide 414-420 of the nSH2 and 704-710 of the cSH2 in the presence of PDGFR pY ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(112, 0), 'end':(112, 9), 'text':'The presence of the nSH2 mutation ( K379E ) exposed'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(112, 10), 'end':(112, 19), 'text':'the p110delta helical domain peptide 524-529 to a similar level'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(112, 20), 'end':(112, 28), 'text':'as when in the presence of PDGFR pY ,'}, {'start':(112, 29), 'end':(112, 58), 'text':'whereas the Y685A mutation exposed the elbow peptide 1023-1033 of the p110delta kinase domain ( C ) , as well as the substrate binding loop peptide 920-935 ( ) .'}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'comparison', 'direction':'LeftToRight', 'children':[{'start':(113, 0), 'end':(113, 18), 'text':'This C-terminal elbow showed a 1.0 Da increase in exchange at 3s of on-exchange in the Y685A mutant complex'}, {'start':(113, 19), 'end':(113, 22), 'text':'compared with wild-type ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(113, 23), 'end':(113, 35), 'text':'and showed a further 1.0 Da increase in the presence of PDGFR pY'}, {'start':(113, 36), 'end':(113, 39), 'text':'( C ) .'}]}]}]}]}]}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(114, 0), 'end':(114, 4), 'text':'The peptide 681-687 in p85alpha'}, {'start':(114, 5), 'end':(114, 20), 'text':'that showed an increase in exchange in the presence of PDGFR pY in wild-type p85alpha ,'}]}, {'start':(114, 21), 'end':(114, 46), 'text':'showed a decrease in exchange for the Y685A construct due to rigidification of the entire cSH2 domain in the presence of PDGFR pY ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(115, 0), 'end':(115, 3), 'text':'This is further evidence'}, {'label':'joint', 'direction':'None', 'children':[{'start':(115, 4), 'end':(115, 17), 'text':'that this p85 region represents a key contact site with the catalytic subunit ,'}, {'start':(115, 18), 'end':(115, 35), 'text':'and that the presence of the Y685A mutation in the cSH2 does not disrupt PDGFR pY binding .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(116, 0), 'end':(116, 22), 'text':'The peptide 444-456 in the iSH2 domain of p85alpha showed a 1.0 Da increase in exchange at 1000s in the double mutant complex'}, {'start':(116, 23), 'end':(116, 25), 'text':'compared to wild-type'}]}, {'start':(116, 26), 'end':(116, 38), 'text':'and was further exposed by the addition of PDGFR pY ( ) .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(117, 0), 'end':(117, 32), 'text':'To test the possible effect of mutations in this region on enzyme activity we expressed the full length complex of p110delta and p85alpha with the previously determined p85alpha oncogenic mutation L449S ( )'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(117, 33), 'end':(117, 34), 'text':'and found'}, {'label':'joint', 'direction':'None', 'children':[{'start':(117, 35), 'end':(117, 42), 'text':'that this mutation increased basal activity ~ 2-fold'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(117, 43), 'end':(117, 48), 'text':'and showed activation by PDGFR pY'}, {'start':(117, 49), 'end':(117, 58), 'text':'that was similar to the wild-type ( B ) .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(118, 0), 'end':(118, 4), 'text':'In addition , cellular assays'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(118, 5), 'end':(118, 18), 'text':'looking at PI3K downstream signaling showed a 2-fold increase in Akt phosphorylation for cells'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(118, 19), 'end':(118, 25), 'text':'transiently cotransfected with the p110delta+ p85alpha Y685A'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(118, 26), 'end':(118, 29), 'text':'compared to the cells'}, {'start':(118, 30), 'end':(118, 37), 'text':'cotransfected with p110delta+ p85alpha ( A ) .'}]}]}]}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(119, 0), 'end':(119, 4), 'text':'Ap110delta+ p85alpha N564D complex ,'}, {'start':(119, 5), 'end':(119, 19), 'text':'carrying a somatic mutation in the iSH2 previously demonstrated to potently activate PI3K signaling ,'}]}, {'start':(119, 20), 'end':(119, 25), 'text':'resulting in oncogenesis ( ) ,'}]}, {'start':(119, 26), 'end':(119, 36), 'text':'showed a similar increase in Akt phosphorylation ( A ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'enablement', 'direction':'RightToLeft', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(120, 0), 'end':(120, 1), 'text':'To determine'}, {'start':(120, 2), 'end':(120, 14), 'text':'if there were any p110 isoform specific differences in regulation by cSH2 ,'}]}, {'start':(120, 15), 'end':(120, 35), 'text':'we purified full-length complexes of human p110alpha , p110beta , and p110delta with and without the Y685A mutation in p85alpha .'}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(121, 0), 'end':(121, 2), 'text':'Enzyme activity assays'}, {'start':(121, 3), 'end':(121, 9), 'text':'performed with 5 % PIP2 liposomes showed'}]}, {'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(121, 10), 'end':(121, 20), 'text':'that both p110delta and p110beta were activated by the mutation ,'}, {'start':(121, 21), 'end':(121, 28), 'text':'whereas p110alpha was not ( B ) .'}]}]}]}]}]}]}]}]}]}]}
12	48	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(0, 0), 'end':(0, 0), 'text':'Introduction'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(1, 0), 'end':(1, 9), 'text':'Phosphoinositide 3-kinases ( PI3Ks ) are a family of enzymes'}, {'start':(1, 10), 'end':(1, 20), 'text':'that catalyze the phosphorylation of the D3-hydroxyl of inositol phospholipids .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 0), 'end':(2, 19), 'text':'The lipid products of the reaction act as second messengers and lead to downstream recruitment of phosphoinositide binding proteins ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 20), 'end':(2, 24), 'text':'which orchestrate many important functions'}, {'start':(2, 25), 'end':(2, 32), 'text':'including cell proliferation and survival ( ) .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(3, 0), 'end':(3, 6), 'text':'PI3Kdelta is upregulated in some leukemias ,'}, {'start':(3, 7), 'end':(3, 26), 'text':'and a specific inhibitor of it ( CAL-101 ) has entered clinical trials for chronic lymphocytic leukemia ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(4, 0), 'end':(4, 5), 'text':'This isoform is abundant in leukocytes'}, {'start':(4, 6), 'end':(4, 16), 'text':'and has important roles in immunity , inflammation and allergy .'}]}, {'label':'background', 'direction':'RightToLeft', 'children':[{'start':(5, 0), 'end':(5, 5), 'text':'Like other class IA PI3Ks ,'}, {'label':'joint', 'direction':'None', 'children':[{'start':(5, 6), 'end':(5, 34), 'text':'it is an obligate heterodimer of a p110 catalytic subunit ( p110delta ) anda p85-type regulatory subunit ( p85alpha , p55alpha , p50alpha , p85beta , or p55gamma )'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(5, 35), 'end':(5, 37), 'text':'and produces PtdIns'}, {'start':(5, 38), 'end':(5, 47), 'text':'( 3,4,5 ) P 3 lipids invivo ( ) .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(6, 0), 'end':(6, 15), 'text':'The p110alpha catalytic subunit is one of the most frequently mutated oncogenes in human tumors ,'}, {'start':(6, 16), 'end':(6, 29), 'text':'and PI3K inhibition is a major pharmacological target for drug discovery ( ) .'}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(7, 0), 'end':(7, 1), 'text':'The cancer'}, {'start':(7, 2), 'end':(7, 5), 'text':'associated p110alpha mutations upregulate'}]}, {'start':(7, 6), 'end':(7, 14), 'text':'the enzyme activity by different mechanisms ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'RightToLeft', 'children':[{'start':(8, 0), 'end':(8, 18), 'text':'Because any one of the regulatory subunits can interact tightly with any of the class IA catalytic subunits ,'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(8, 19), 'end':(8, 22), 'text':'it is generally assumed'}, {'start':(8, 23), 'end':(8, 33), 'text':'that all p110 subunits are inhibited in the same way .'}]}]}, {'start':(9, 0), 'end':(9, 17), 'text':'The importance of understanding isoform specific regulation of PI3Ks by p85 led us to examine this assumption .'}]}, {'label':'contrast', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(10, 0), 'end':(10, 30), 'text':'All of the p110 subunits consist of an adaptor binding domain ( ABD ) , a Ras binding domain ( RBD ) , a C2 domain , a helical domain ,'}, {'start':(10, 31), 'end':(10, 44), 'text':'and a kinase domain split into an N-lobe and a C-lobe ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 0), 'end':(11, 13), 'text':'The p85 subunits consist of an N-terminal SH3 domain , a breakpoint cluster region'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 14), 'end':(11, 18), 'text':'( BCR ) homology domain'}, {'label':'joint', 'direction':'None', 'children':[{'start':(11, 19), 'end':(11, 25), 'text':'flanked by two proline rich regions ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 26), 'end':(11, 34), 'text':'and two SH2 domains , nSH2 and cSH2 ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 35), 'end':(11, 39), 'text':'separated by a coiled-coil region'}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 40), 'end':(11, 43), 'text':'termed the inter-SH2 domain'}, {'start':(11, 44), 'end':(11, 46), 'text':'( iSH2 )'}]}, {'start':(11, 47), 'end':(11, 52), 'text':'( see available online ) .'}]}]}]}]}]}]}, {'start':(12, 0), 'end':(12, 25), 'text':'The ABD domain has been shown to be necessary and sufficient to bind the regulatory subunit , through interactions with the iSH2 domain ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(13, 0), 'end':(13, 12), 'text':'The regulatory subunits stabilize the catalytic subunit , inhibit its basal activity ,'}, {'start':(13, 13), 'end':(13, 39), 'text':'and activate PI3K in the presence of phosphorylated tyrosine ( pY ) sequences in activated receptor tyrosine kinases ( RTKs ) and adaptor proteins ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(14, 0), 'end':(14, 18), 'text':'The N-terminal SH2 domain ( nSH2 ) in combination with the iSH2 domain is the minimal construct of p85alpha'}, {'start':(14, 19), 'end':(14, 28), 'text':'required to inhibit the activity of p110alpha ( ) .'}]}, {'start':(15, 0), 'end':(15, 9), 'text':'This inhibition can be relieved by RTK pY peptides .'}]}, {'label':'comparison', 'direction':'LeftToRight', 'children':[{'start':(16, 0), 'end':(16, 14), 'text':'Constructs of the p110alpha isoform with oncogenic mutations in the helical domain display increased activity'}, {'label':'joint', 'direction':'None', 'children':[{'start':(16, 15), 'end':(16, 19), 'text':'compared to the wild-type enzyme'}, {'start':(16, 20), 'end':(16, 34), 'text':'and have no further increase in activity on RTK pY peptide binding ( ) .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(17, 0), 'end':(17, 17), 'text':'However , regulation of the p110delta isoform by p85 and RTK pY peptides has not been examined .'}, {'start':(18, 0), 'end':(18, 15), 'text':'Understanding the dynamics between the catalytic and regulatory subunits is central to understanding PI3K activity .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(19, 0), 'end':(19, 39), 'text':'The structures of both the isolated nSH2 and cSH2 domains of p85alpha with and without RTK pY peptides are known ( ) , as well as the structure of the niSH2 fragment bound to the full-length p110alpha ( ) .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(20, 0), 'end':(20, 9), 'text':'The nSH2 domain binds the helical domain through the surface'}, {'start':(20, 10), 'end':(20, 15), 'text':'required for pY peptide binding ,'}]}, {'start':(20, 16), 'end':(20, 36), 'text':'and consequently the presence of a pY peptide breaks the inhibitory contacts between the catalytic and regulatory subunits ( ) .'}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(21, 0), 'end':(21, 3), 'text':'Many of the cancer'}, {'start':(21, 4), 'end':(21, 5), 'text':'linked mutations'}]}, {'start':(21, 6), 'end':(21, 51), 'text':'identified are located at two separate interfaces between the p110 catalytic and p85alpha subunits , one between the iSH2 domain of p85 and the C2 domain of p110alpha , and one between the nSH2 domain of p85 and the helical domain of p110alpha ( ) .'}]}]}]}, {'start':(22, 0), 'end':(22, 17), 'text':'However , no structural information exists for possible interactions between the nSH2 and cSH2 domains with p110delta .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'RightToLeft', 'children':[{'start':(23, 0), 'end':(23, 18), 'text':'The recently published structures of the free p110delta catalytic subunit ( ) contributed to developing isotype specific inhibitors ,'}, {'start':(23, 19), 'end':(23, 32), 'text':'but they shed no light on how this isoform is regulated by p85 .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(24, 0), 'end':(24, 12), 'text':'Toward this end , we used deuterium exchange mass spectrometry ( DXMS )'}, {'start':(24, 13), 'end':(24, 22), 'text':'to explore the interactions between the p110delta and p85alpha .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(25, 0), 'end':(25, 16), 'text':'Due to recent advances in instrumentation and analysis , DXMS has become a burgeoning and powerful method'}, {'start':(25, 17), 'end':(25, 34), 'text':'for examining protein folding , protein protein contacts , protein-ligand binding , and conformational changes ( ) .'}]}, {'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(26, 0), 'end':(26, 5), 'text':'This technique has also been used'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(26, 6), 'end':(26, 10), 'text':'to study membrane associated enzymes'}, {'start':(26, 11), 'end':(26, 17), 'text':'interacting with phospholipid vesicles ( ) .'}]}]}]}]}, {'label':'background', 'direction':'RightToLeft', 'children':[{'start':(27, 0), 'end':(27, 2), 'text':'Using DXMS ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(27, 3), 'end':(27, 7), 'text':'we have localized p110delta regions'}, {'start':(27, 8), 'end':(27, 17), 'text':'interacting with the iSH2 , nSH2 and cSH2 domains .'}]}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(28, 0), 'end':(28, 4), 'text':'Our lipid kinase assays suggest'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(28, 5), 'end':(28, 13), 'text':'that full inactivation of p110delta requires a p85 construct'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(28, 14), 'end':(28, 17), 'text':'encompassing both SH2 domains'}, {'start':(28, 18), 'end':(28, 21), 'text':'( nicSH2 ) .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(29, 0), 'end':(29, 8), 'text':'Binding of RTK pY peptides to the SH2 domains'}, {'start':(29, 9), 'end':(29, 22), 'text':'exposed p110delta regions protected by the nSH2 and cSH2 domains to deuterium exchange ,'}]}, {'start':(29, 23), 'end':(29, 30), 'text':'leading to full activation of all constructs .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(30, 0), 'end':(30, 9), 'text':'DXMS results enabled us to create a p85 point mutant'}, {'start':(30, 10), 'end':(30, 19), 'text':'that exposes the proposed cSH2 binding site on p110delta ,'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(30, 20), 'end':(30, 25), 'text':'circumventing downregulation by the cSH2 invitro'}, {'start':(30, 26), 'end':(30, 32), 'text':'and increasing downstream signaling in cells .'}]}]}, {'start':(31, 0), 'end':(31, 12), 'text':'Importantly , this same mutation also activates p110beta , but not p110alpha .'}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(32, 0), 'end':(32, 11), 'text':'Combining this cSH2 mutation with an oncogenic mutation in the nSH2 ,'}, {'start':(32, 12), 'end':(32, 17), 'text':'which exposed the helical domain ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(32, 18), 'end':(32, 21), 'text':'results in a p85'}, {'start':(32, 22), 'end':(32, 26), 'text':'that fully activated p110delta .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'RightToLeft', 'children':[{'start':(33, 0), 'end':(33, 3), 'text':'Using FRET measurements ,'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(33, 4), 'end':(33, 5), 'text':'we find'}, {'label':'contrast', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(33, 6), 'end':(33, 16), 'text':'that p110delta and p85alpha complex binds very poorly to lipid vesicles'}, {'start':(33, 17), 'end':(33, 21), 'text':'mimicking plasma membrane composition ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(33, 22), 'end':(33, 33), 'text':'but pY peptides greatly increased affinity of the complex for lipids ,'}, {'start':(33, 34), 'end':(33, 41), 'text':'especially when the vesicles contained PIP2 substrate .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(34, 0), 'end':(34, 18), 'text':'DXMS also enabled us to identify for the first time specific regions in both the catalytic and regulatory subunits'}, {'start':(34, 19), 'end':(34, 24), 'text':'that interact with lipid membranes .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(35, 0), 'end':(35, 18), 'text':'Interestingly , some regions of the ABD domain and iSH2 become more exposed in the presence of membrane ,'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(35, 19), 'end':(35, 19), 'text':'indicating'}, {'start':(35, 20), 'end':(35, 30), 'text':'that loosening of interactions within the complex accompanies membrane binding .'}]}]}]}
